Luciferase and ChIP assays indicated that PRDM16 exhibits antitumor activities in PTC as a transcription factor through binding to PC promoter, thus inhibiting PC promoter activity at the transcriptional level and further suppressing the EMT process of PTC tumor cells. The gene discussed is PRDM16; the disease is pachyonychia congenita.